Clinical benefits and cost-effectiveness of 17-year treatment with low-dose interferon-alpha 2b in a patient with chronic hepatitis C: a case report.
Kawaguchi
Takumi
T
Department of Digestive Disease Information and Research, Kurume University School of Medicine, 67 Asahi-machi, Kurume, 830-0011, Japan. takumi@med.kurume-u.ac.jp
Sumie
Shuji
S
Itou
Minoru
M
Taniguchi
Eitaro
E
Matoba
Tsunetaka
T
Sata
Michio
M
D000998:Antiviral Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000191:economics; D003362:Cost-Benefit Analysis; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage* / Q000009:adverse effects / Q000191:economics; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins